Approved Pfizer breast cancer drug impresses in latest study
April 15, 2015 at 12:58 PM EDT
April 15 (Reuters) - Pfizer Inc said on Wednesday the first formal late-stage trial of its approved treatment for advanced breast cancer, Ibrance, was stopped early after the medicine met its goal of delaying progression of the disease in previously treated patients.